Breaking News Instant updates and real-time market news.

GPS

Gap

$26.05

(0.00%)

, BBBY

Bed Bath & Beyond

$12.26

(0.00%)

09:40
01/10/19
01/10
09:40
01/10/19
09:40

Unusually active option classes on open January 10th

Unusual total active option classes on open include: MSCI Emerging Markets Index (.MXEF), Gap (GPS), Bed Bath & Beyond (BBBY), Target (TGT), Eli Lilly (LLY), SPDR S&P Retail (XRT), Canopy Growth (CGC), United Continental (UAL), Twitter (TWTR), and AMD (AMD).

GPS

Gap

$26.05

(0.00%)

BBBY

Bed Bath & Beyond

$12.26

(0.00%)

TGT

Target

$70.31

(0.00%)

LLY

Eli Lilly

$117.30

(0.00%)

XRT

S&P Retail Index SPDR

$44.33

(0.00%)

CGC

Canopy Growth

$33.64

(0.00%)

UAL

United Continental

$83.77

(0.00%)

TWTR

Twitter

$32.24

(0.00%)

AMD

AMD

$20.18

(0.00%)

  • 14

    Jan

  • 16

    Jan

  • 28

    Jan

  • 18

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 18

    May

GPS Gap
$26.05

(0.00%)

11/26/18
KEYB
11/26/18
NO CHANGE
KEYB
Holiday season got off to healthy start, says KeyBanc
KeyBanc analyst Edward Yruma thinks the holiday shopping season got off to a healthy start as online continues to grab incremental share given the normalization of promotions across physical and digital channels. The analyst notes that traffic levels were stable across his store checks, and his initial observations point to the potential for a strong holiday season. Across his coverage, standouts include Walmart (WMT), Old Navy (GPS), and Urban Outfitters (URBN). Lululemon (LULU) had website difficulties when it launched its Black Friday promos on Thursday, he notes, while Gap and Victoria's Secret (LB) both seemed soft.
11/28/18
MKMP
11/28/18
NO CHANGE
Target $30
MKMP
Neutral
Gap price target lowered to $30 from $32 at MKM Partners
MKM Partners analyst Roxanne Meyer lowered her price target on Gap to $30 and kept her Neutral rating after its Q3 earnings last week. The analyst notes that the results were a "mixed bag" with sequentially improving comps but lower gross margin and higher SG&A costs. Meyer adds that Banana Republic is recovering, with consecutive quarters of positive comps and indications of accelerating momentum in Q4, but the Gap brand comps were worse than expected, with the closing of underperforming stores being potentially "just a first step".
12/20/18
WEDB
12/20/18
NO CHANGE
Target $25
WEDB
Neutral
Gap goes 'from naughty to nice' as Big data forecasts inflection, says Wedbush
Wedbush analyst Jen Redding says Gap "goes from naughty to nice" as her firm's Big data forecasts inflection from a gross margin miss into the third-quarter print to a gross margin run-rate now tracking ahead of consensus in mid fourth-quarter. The Black Friday holiday shopping period was strong, and she is now tracking upside to holiday business, as her data model forecasts approximately 90 bps in gross margin upside to 37.28% versus street expectations for 36.34%. Redding reiterates a Neutral rating and $25 price target on the shares.
01/02/19
JEFF
01/02/19
NO CHANGE
JEFF
Buy Gap, sell L Brands are Jefferies' best Consumer ideas for 2019
In the Consumer space, Jefferies analyst Randal Konik says his best ideas for 2019 are buying Gap (GPS) and selling L Brands (LB). The analyst recommends using the late 2018 selloff as an opportunity to get long consumer names for 2019. His other top Buy ideas are American Eagle (AEO), Boot Barn (BOOT), Capri Holdings (CPRI), Five Below (FIVE), Foot Locker (FL), Fox Factory (FOXF), Acushnet Holdings (GOLF), Kohl's (KSS), Manchester United (MANU), Ollie's Bargain Outlet (OLLI), Tiffany (TIF), Urban Outfitters (URBN), Under Armour (UAA) and Yeti (YETI). On L Brands, Konik continues to believe Victoria's Secret "is broken," Pink "is a fad" that's sales will get cut in half, and Bath & Body Works is at a "cyclical peak with daunting compares ahead." On the flip side, the analyst thinks Gap will be one of the top S&P 500 stocks in 2019. He recommends "aggressively" buying the shares at current levels.
BBBY Bed Bath & Beyond
$12.26

(0.00%)

01/02/19
LOOP
01/02/19
NO CHANGE
Target $12
LOOP
Hold
Loop Capital says Bed Bath Beyond, Amazon price gap widens to historical levels
Loop Capital analyst Anthony Chukumba kept his Hold rating and $12 price target on Bed Bath & Beyond (BBBY), saying his periodic pricing study demonstrated that the gap between the company and Amazon.com (AMZN) has widened back to its "historical level". The analyst sees this as a likely negative for the former, but also notes that that discounting has been a challenge in maintaining its gross margins. Chukumba maintains his forecasts on Bed Bath results ahead of next week's earnings, adding that while its stock trades at a discount to historical average levels, the 6.5-times expected forward earnings multiple is "in line" with other "secularly challenged specialty hardlines retailers."
11/08/18
SBSH
11/08/18
NO CHANGE
Target $13
SBSH
Sell
Bed Bath & Beyond activist probability low, 'screens well' for LBO, says Citi
Citi analyst Kate McShane reiterated a Sell rating on Bed Bath & Beyond shares, noting that the company has faced and continues to face significant challenges despite having enacted a number of changes in recent years. She views activist involvement or an LBO as a low probability given the number of challenges faced, but added that Bed Bath "has always screened well" as an LBO candidate. In a leveraged buyout scenario, the company could cut the dividend, shut down stores and create a smaller store format as a private company, McShane said.
10/02/18
LOOP
10/02/18
NO CHANGE
Target $15
LOOP
Hold
Bed Bath & Beyond pricing gap with Amazon narrowed in August, says Loop Capital
Loop Capital analyst Anthony Chukumba kept his Hold rating and $15 price target on Bed Bath & Beyond (BBBY), saying his channel checks indicate a further narrowing of the pricing gap with Amazon (AMZN). The analyst notes the gap in August has shrunk to 13.6% on average vs. 16.9% in July, but also warns that given its position as the "most dynamic retailer" in the U.S. in terms of pricing, Amazon can "quickly and easily lower prices if top-line growth underperforms".
10/01/18
ARGS
10/01/18
DOWNGRADE
ARGS
Hold
Bed Bath & Beyond downgraded to Hold from Buy at Argus
Argus analyst Christopher Graja downgraded Bed Bath & Beyond to Hold after lowering his earnings estimates to reflect on ongoing gross margin pressure, declines in store traffic and spending on systems and consultants. The disappointing Q2 results amid a very strong retail environment is a concern, Graja tells investors in a research note. The analyst is no longer confident in management's ability to focus on the company's long-term objectives.
TGT Target
$70.31

(0.00%)

12/20/18
BARD
12/20/18
NO CHANGE
Target $2100
BARD
Outperform
Amazon fee changes should improve selection, volume, says Baird
After Amazon (AMZN) announced changes to marketplace referral fees, or take rates, as well as fulfillment and storage fees for fulfillment by Amazon, which will take effect in mid-February, Baird analyst Colin Sebastian says he thinks the fee changes should improve production selection and volume while offsetting higher delivery costs. Sebastian tells investors in a research note that he believes the Amazon Marketplace could be more competitive with traditional retailers such as Walmart (WMT) and Target (TGT), which currently sell significant volumes of consumables, and with online vertical sites such as Wayfair (W) in the Furniture/Home Decor category. He maintains an Outperform rating and $2,100 price target on Amazon shares.
12/26/18
STPT
12/26/18
UPGRADE
STPT
Buy
Target upgraded to Buy from Hold at Standpoint Research
Standpoint Research analyst Ronnie Moas upgraded Target to Buy from Hold.
01/07/19
BARD
01/07/19
NO CHANGE
Target $86
BARD
Outperform
Target poses 'compelling value idea', says Baird
Baird analyst Peter Benedict kept his Outperform rating and $86 price target on Target, saying its stock "still offers good value" and represents a "compelling" investment idea going into the company's holiday sales update on Thursday. The analyst expects the company to continue to "benefit from multiple top-line initiatives, demonstrating progress toward operating margin stabilization" with "only a modest contraction" of about 10bps next year. The analyst is also positive on Target's recent traffic and comp growth, which he calls "amongst the best in retail", as well as market share gains across all major categories.
01/10/19
BARD
01/10/19
NO CHANGE
Target $86
BARD
Outperform
Target remains compelling value idea, says Baird
Baird analyst Peter Benedict noted Target reported strong holiday sales and reaffirmed its Q4 earnings and guidance. He remains encouraged by its continued robust traffic and sales momentum, which reflects market share gains fueled by a number of top-line initiatives. Benedict reiterated his Outperform rating on Target and said it remains a compelling value idea. Benedict has an $86 price target on Target shares.
LLY Eli Lilly
$117.30

(0.00%)

12/27/18
ARGS
12/27/18
NO CHANGE
Target $135
ARGS
Buy
Argus sees volume growth, expanded indications as 2019 catalysts for Eli Lilly
Argus analyst David Toung kept his Buy rating and $135 price target on Eli Lilly, saying its 2019 catalysts for upside include anticipated volume growth and expanded indications for existing drugs, along with "potential regulatory approvals". The analyst notes that while the company's mature products are seeing slower sales and face patent expiration and the loss of exclusivity, he also expects Eli Lilly to generate earnings growth from margin expansion. Toung is also confident in 2019 contribution of Eli Lilly's recently launched Olumiant for rheumatoid arthritis, Verzenio for the second-line treatment of breast cancer, and Taltz for active psoriatic arthritis.
12/31/18
CANT
12/31/18
NO CHANGE
Target $53
CANT
Overweight
Doctors impressed by tanezumab data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says that investors she's spoken with are expecting the data for Pfizer (PFE) and Eli Lilly's (LLY) tanezumab in the first half of 2019 to be similar to or worse than what was seen in the first Phase 3 data set reported on October 23. However, physicians are impressed by the data and do not believe the rapidly progressive osteoarthritis imbalance would impact their desire to prescribe tanezumab if it is approved, Chen tells investors in a research note. The analyst believes the safety for tanezumab will be better than expected and that the drug could replace opioids for the treatment of pain. If that is right, peak sales potential of tanezumab could be billions of dollars, and drive upside to modest expectations for the drug, says the analyst. She keeps an Overweight rating on Pfizer with a $53 price target.
01/07/19
PIPR
01/07/19
NO CHANGE
Target $235
PIPR
Overweight
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
01/08/19
SBSH
01/08/19
DOWNGRADE
Target $235
SBSH
Neutral
Loxo Oncology downgraded to Neutral from Buy at Citi
Citi analyst Yigal Nochomovitz downgraded Loxo Oncology (LOXO) to Neutral saying the company is unlikely to receive a competing takeover bid. The analyst raised his price target for the shares to $235 from $201 to reflect the takeover agreement by Eli Lilly (LLY). He believes Mirati Therapeutics (MRTX) is another potential takeover candidate in the oncology space.
XRT S&P Retail Index SPDR
$44.33

(0.00%)

CGC Canopy Growth
$33.64

(0.00%)

01/10/19
GSCO
01/10/19
UPGRADE
Target $211
GSCO
Buy
Constellation Brands upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Judy Hong upgraded Constellation Brands (STZ) to Buy while lowering her price target for the shares to $211 from $243. The stock closed yesterday down 12.5%, or $21.57, to $150.94 post the company's Q3 earnings report. Constellation is down over 30% in the past 12 months, mostly driven by multiple contraction, Hong tells investors in a research note. The analyst reduced her estimates to reflect a "softer outlook" but sees a "compelling" risk/reward at current share levels. Her model yields a $195 per share value for the core business excluding Canopy Growth (CGC) and a consolidated price target of $211, pointing to 40% upside. Beer sales growth should remain healthy and beer margins should improve in fiscal 2020 as cost headwinds are lapped, Hong contends. Further, she believes Constellation shares could outperform even if investors assign zero value to its investment in Canopy.
01/10/19
RHCO
01/10/19
NO CHANGE
Target $165
RHCO
Hold
Constellation Brands price target lowered to $165 from $180 at SunTrust
SunTrust analyst William Chappell lowered his price target on Constellation Brands (STZ) to $165 and kept his Hold rating on the stock. The analyst cites the company's reported expectations of declining wine and spirits sales, adding that the latest $4B investment in Canopy Growth (CGC) will be the "cloud" hanging over the stock for the next few quarters because of the uncertainty related to its potential growth.
01/10/19
WELS
01/10/19
NO CHANGE
Target $235
WELS
Market Perform
Constellation Brands price target lowered to $235 from $260 at Wells Fargo
Wells Fargo analyst Bonnie Herzog lowered her price target for Constellation Brands (STZ) to $235 from $260 following "disappointing' Q3 results and FY19 guide down. The continues to view the stock as best-in-class with huge potential upside from its cannabis investment and therefore believes the sharp selloff in the shares is "way overdone!" However, Constellation Brands' miss on beer depletions, guide down on FY19 beer OI margin, pressure on its wine biz and lack of visibility on the impact of its Canopy Growth (CGC) investment on earnings will likely "keep the bears growling near-term." Herzog reiterates an Outperform rating on Constellation Brands' shares.
01/10/19
JEFF
01/10/19
NO CHANGE
Target $258
JEFF
Buy
Constellation risk/reward remains favorable after selloff, says Jefferies
Jefferies analyst Kevin Grundy lowered his estimates for Constellation Brands following yesterday's fiscal 2019 guidance reduction but he believes the stock's risk/reward remains favorable. The analyst lowered his price target for the shares to $258 from $269 and keeps a Buy rating on Constellation. The company's beer business remains healthy and its investment in Canopy Growth (CGC) is now a free call option, Grundy tells investors in a research note.
UAL United Continental
$83.77

(0.00%)

01/10/19
JPMS
01/10/19
NO CHANGE
JPMS
JPMorgan upgrades United and Alaska Air, downgrades JetBlue
JPMorgan analyst Jamie Baker raised his 2019 estimates "across the board" for the U.S. Airlines ahead of next week's earnings kickoff. However, he says the earnings raises are for the "wrong reasons," namely cheaper fuel and softer RASM. JetBlue Airways' (JBLU) forecasted upside potential falls below 10% after the analyst reduced his target multiples. As such, he downgraded the shares to Neutral from Overweight. The analyst also upgraded Alkaska Air Group (ALK) to Neutral from Underweight rating saying his 2020 earnings forecast for the company is the only one to rise materially. In addition, the analyst upgraded United Continental Holdings (UAL) to Overweight from Neutral. The analyst sees an attractive risk/reward profile following the stock's 14% selloff from just five weeks ago.
01/10/19
JPMS
01/10/19
UPGRADE
Target $95
JPMS
Overweight
United Continental upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jamie Baker upgraded United Continental Holdings to Overweight with a $95 price target.
01/09/19
01/09/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Nike (NKE) downgraded to Neutral from Outperform at Baird with analyst Jonathan Komp citing its relative valuation and concerns about its high P/E premium. 2. Oracle (ORCL) downgraded to Equal Weight from Overweight at Barclays with analyst Raimo Lenscho saying the competitive situation in the company's core database market and cloud is "not getting easier." 3. Wendy's (WEN) downgraded to Neutral from Outperform at Wedbush. 4. Booking Holdings (BKNG) downgraded to Equal Weight from Overweight at Morgan Stanley and to Hold from Buy at Jefferies. 5. United Continental (UAL) downgraded to Underperform from In-Line at Imperial Capital while Delta Air Lines (DAL) was downgraded to In-Line from Outperform. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/19
IMPC
01/09/19
DOWNGRADE
Target $73
IMPC
Underperform
United Continental downgraded to Underperform from In-Line at Imperial Capital
Imperial Capital analyst Michael Derchin downgraded United Continental Holdings (UAL) to Underperform and lowered his price target for the shares to $73 from $110. Following Delta's (DAL) Q4 update, further declines in fuel prices and recent market volatility, the analyst reduced his valuations and unit revenue expectations "across the board to reflect conservatism." Among his baseline industry assumptions is the expectation for fewer fare increases by low cost carriers due to lower oil prices. United's unit revenue momentum is likely to slow meaningfully through fiscal 2020, resulting in shares trading at similar valuations as American Airlines (AAL), Derchin tells investors in a research note.
TWTR Twitter
$32.24

(0.00%)

01/10/19
JPMS
01/10/19
NO CHANGE
Target $44
JPMS
Overweight
Twitter named a 2019 best Internet idea at JPMorgan
JPMorgan analyst Doug Anmuth names Twitter (TWTR) a best Internet idea for 2019 along with Facebook (FB) and Amazon.com (AMZN). Twitter shares increased 20% in 2018 on "continued solid" daily active user growth, "significant" revenue re-acceleration following 2017 declines, and the company's first full year of GAAP profitability, Anmuth tells investors in a research note. Going into 2019, he believes Twitter is making "meaningful progress on its health work identifying malicious and spammy content." Quality improvements should drive benefits to usage and advertising revenue long-term, adds the analyst. Further, Anmuth's channel checks suggest Twitter's advertising products and improving return on investment "are increasingly resonating with marketers." The analyst lowered his price target for the shares to $44 from $45 and keeps an Overweight rating on Twitter. The stock closed yesterday up 44c to $32.25 and is up 3% in premarket trading to $33.26 after BofA/Merrill analyst Justin Post double upgraded his rating on Twitter to Buy from Underperform.
01/10/19
01/10/19
UPGRADE
Target $39

Buy
BofA/Merrill upgrades Twitter two notches to Buy following social user survey
As previously reported, BofA Merrill Lynch analyst Justin Post upgraded Twitter (TWTR) two notches, to Buy from Underperform, after conducting a survey in early December of more than 1,000 U.S. consumers ages 18-65. The survey showed Twitter penetration increased to 48% of respondents and the percentage of users reporting deceased usage fell slightly. Improving metrics in the 18-29 demographic suggest more younger users are turning to Twitter, noted Post. The analyst, who sees Twitter as a strong play on video ad dollars shifting online and advertisers potentially diversifying their ad spending, raised his price target on Twitter shares to $39. Post added in the note to investors that the survey suggested Google (GOOGL) and Facebook's (FB) Instagram have the most positive usage trends, while the negative effects from Snap's (SNAP) redesign appear to have continued.
01/10/19
BOFA
01/10/19
UPGRADE
BOFA
Buy
Twitter upgraded to Buy from Underperform at BofA/Merrill
01/09/19
JEFF
01/09/19
NO CHANGE
JEFF
Jefferies says be selective in Internet, cuts targets on Snap and Facebook
Jefferies analyst Brent Thill this morning cut his price targets on a handful of names in the Internet space. In a research note titled "2019 Playbook," the analyst also downgraded Booking Holdings (BKNG) and Redfin (RDFN) to Hold from Buy. Thill tells investors to selective in the space, and recommends buying Amazon.com (AMZN), Alphabet (GOOGL) and Intuit (INTU) in large cap, Match Group (MTCH), IAC (IAC) and GoDaddy (GDDY) in mid cap, and Wix.com (WIX) and Trade Desk (TTD) in small cap. He expects TripAdvisor (TRIP), Shutterstock (SSTK) and Shutterstock (EIGI) to underperform. Among his price target cuts were Buy-rated Expedia (EXPE) to $150, Buy-rated Facebook to $180, Hold-rated Snap (SNAP) to $7, Hold-rated Sonos (SONO) to $12, Hold-rated Twitter (TWTR) to $33 and Hold-rated Zillow Group (ZG) to $34.
AMD AMD
$20.18

(0.00%)

01/04/19
01/04/19
UPGRADE
Target $60

Buy
BofA/Merrill prefers cloud and 5G exposure in semis, upgrades Intel to Buy
As previously reported, BofA Merrill Lynch analyst Vivek Arya upgraded Intel (INTC) to Buy from Neutral, stating that the stock provides attractive exposure to growth trends in cloud computing, AI, advanced autos and 5G. He forecasts total semiconductor industry sales to decelerate to down 3% year-over-year in 2019 and still expects enterprise, data center and parts of networking infrastructure to perform better than cyclical sectors such as industrial, automotive and smartphones, Arya tells investors. Risks, such as AMD (AMD) share loss, 7nm product delays, and tougher PC/data center comps, do exist, but now appear to be reflected in Intel shares, the analyst added. He raised his price target on Intel shares to $60 from $52.
12/27/18
RBCM
12/27/18
NO CHANGE
Target $200
RBCM
Outperform
Nvidia, AMD estimates lowered at RBC Capital on more cautious gaming view
RBC Capital analyst Mitch Steves lowered his price target on Nvidia (NVDA) to $200 from $230 and also lowered his FY19 revenue forecast on Advanced Micro Devices (AMD) to $7.29B from $7.41B. The analyst says the revisions reflect his observation of a reduction in average selling prices for GPUs of both companies in the secondary market, particularly for Nvidia's GTX 1070 gaming chip. Steves warns that the company may not be able to discern whether the lower prices come as a result of reduced demand in gaming or cryptocurrency related activity, but states that his expectations for Gaming sector are "conservative". The analyst also expects both Nvidia and AMD stocks to remain range bound until the air-pocket in gaming has passed over the near term. Longer term, Steves keeps his Outperform rating on Nvidia amid the sales mix shift toward Data Center revenues, which is seeing traction with the expected annualized growth. For AMD, the analyst also maintains an Outperform rating stating that its long-term investment story remains unchanged. In Q1, Steves sees AMD catalysts in the form a new server product with competitive performance and price relative to the current Intel (INTC) offerings.
12/21/18
DAIW
12/21/18
INITIATION
Target $26
DAIW
Buy
AMD initiated with a Buy at Daiwa
Daiwa initiated AMD with a Buy and $26 price target.
12/20/18
BOFA
12/20/18
NO CHANGE
Target $27
BOFA
Buy
BofA/Merrill sees prolonged weakness in GPUs, lowers AMD price target to $27
BofA Merrill Lynch analyst Vivek Arya said his recent checks suggests there will be prolonged weakness in GPUs over the next few quarters and he trimmed his Q4 and 1H19 sales and EPS estimates for AMD in response. He expects a recovery starting in Q3 in graphics and more backend weighted growth from AMD's next-gen EPYC server chip, "Rome," Arya tells investors. The analyst, who lowered his 2018 EPS estimate by 2c to 44c, which is below the Street at 46c, and lowered his 2019 EPS by 8c to be in-line with consensus at 62c, cut his price target on AMD shares to $27 from $30. Arya keeps a Buy rating on AMD.

TODAY'S FREE FLY STORIES

02:50
01/22/19
01/22
02:50
01/22/19
02:50
General news
FX Update: The Dollar and Yen have traded firmer »

FX Update: The Dollar…

WOLWF

Woolworths Group

$0.00

(0.00%)

18:51
01/21/19
01/21
18:51
01/21/19
18:51
Downgrade
Woolworths Group rating change at Citi »

Woolworths Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLESY

Lendlease Group

$0.00

(0.00%)

18:48
01/21/19
01/21
18:48
01/21/19
18:48
Upgrade
Lendlease Group rating change at Citi »

Lendlease Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFSC

Enterprise Financial

$41.41

0.99 (2.45%)

17:56
01/21/19
01/21
17:56
01/21/19
17:56
Earnings
Enterprise Financial reports Q4 EPS $1.02, consensus 95c »

Reports Q4 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FB

Facebook

$150.01

1.77 (1.19%)

16:36
01/21/19
01/21
16:36
01/21/19
16:36
Periodicals
Facebook planning to add 1,000 jobs in Ireland by year-end, Reuters says »

Facebook will hire an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

FB

Facebook

$150.01

1.77 (1.19%)

16:33
01/21/19
01/21
16:33
01/21/19
16:33
Periodicals
Facebook's WhatsApp limits users to five text forwards, Reuters reports »

Facebook's WhatsApp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

ENB

Enbridge

$36.10

0.425 (1.19%)

16:28
01/21/19
01/21
16:28
01/21/19
16:28
Periodicals
Enbridge gas pipeline explosion creates fireball in Ohio, Reuters says »

An explosion of an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LIN

Linde plc

$160.76

3.48 (2.21%)

16:25
01/21/19
01/21
16:25
01/21/19
16:25
Periodicals
Linde Plc to launch $6B share buyback scheme, Reuters says »

Linde Plc said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

HENKY

Henkel

$0.00

(0.00%)

16:01
01/21/19
01/21
16:01
01/21/19
16:01
Downgrade
Henkel rating change at Goldman Sachs »

Henkel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAG

Conagra Brands

$21.58

0.34 (1.60%)

14:06
01/21/19
01/21
14:06
01/21/19
14:06
Hot Stocks
Conagra exploring alternatives for Italian-based frozen pasta business »

Conagra Brands announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

13:15
01/21/19
01/21
13:15
01/21/19
13:15
General news
IMF trimmed global growth amid "no-deal" Brexit and trade war concerns »

IMF trimmed global growth…

UQM

UQM Technologies

$1.10

0.05 (4.76%)

13:05
01/21/19
01/21
13:05
01/21/19
13:05
Hot Stocks
UQM Technologies acquired by Danfoss Power Solutions for $1.71 per share »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$41.50

-0.54 (-1.28%)

12:37
01/21/19
01/21
12:37
01/21/19
12:37
Hot Stocks
Sanofi granted U.K. marketing authorization for TIV High Dose »

U.K. marketing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

RTN

Raytheon

$165.11

2.285 (1.40%)

12:33
01/21/19
01/21
12:33
01/21/19
12:33
Hot Stocks
Raytheon awarded $24.36M order for F/A-18 aircraft system repair »

Raytheon said it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.80

-0.11 (-0.48%)

11:26
01/21/19
01/21
11:26
01/21/19
11:26
Hot Stocks
Independent Bank boosts quarterly dividend by 20% to 18c »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

11:25
01/21/19
01/21
11:25
01/21/19
11:25
General news
FX Update: The dollar majors have been directionally challenged »

FX Update: The dollar…

EDIT

Editas Medicine

$26.16

-0.01 (-0.04%)

11:25
01/21/19
01/21
11:25
01/21/19
11:25
Hot Stocks
Editas Medicine announces publication of EDIT-101 data in Nature Medicine »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

, GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

11:23
01/21/19
01/21
11:23
01/21/19
11:23
Hot Stocks
France's National Data Protection Commission fines Google 50M euros »

France's National…

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

LAD

Lithia Motors

$87.13

1.57 (1.84%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
Lithia Motors to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 13

    Feb

  • 14

    Mar

CYDY

CytoDyn

$0.00

(0.00%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ABT

Abbott

$71.43

0.9 (1.28%)

09:50
01/21/19
01/21
09:50
01/21/19
09:50
Hot Stocks
Abbott announces FDA approval of TactiCath Contact Force Ablation Catheter »

Abbott announced FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Jan

SFUN

Fang Holdings

$1.88

-0.01 (-0.53%)

09:48
01/21/19
01/21
09:48
01/21/19
09:48
Hot Stocks
Fang announces management changes, proposed China Index spin-off »

Fang Holdings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TS

Tenaris

$24.32

0.64 (2.70%)

09:45
01/21/19
01/21
09:45
01/21/19
09:45
Hot Stocks
Tenaris closes acquisition of 47.79% of Saudi Steel Pipe shares »

Tenaris S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.17

-0.31 (-2.14%)

09:42
01/21/19
01/21
09:42
01/21/19
09:42
Hot Stocks
Pan American reports 2018 silver production 24.8M ounces »

Pan American Silver Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.